Pharma

Pharma companies have been eying digital health with interest, and the first quarter of 2018 was no exception.

ActiGraph activity monitors and a mobile app from Clinical Ink are are at the heart of a newly announced pilot study backed by Bayer, according to a statement released today by ActiGraph.

Five healthcare organizations including insurers UnitedHealthcare and Humana, Optum, Quest Diagnostics, and MultiPlan are launching a blockchain pilot to help payers tackle mandated provider directories.

Pfizer announced today that it is receiving applications for its Pfizer Healthcare Hub: London competitive grant.

Walmart is reportedly in talks to acquire PillPack, a New England-based virtual pharmacy with around $100 million in funding.

Platinum Equity, a Los Angeles-based global investment firm focused on mergers, acquisitions, and operations, has made a binding offer to acquire Johnson & Johnsons' Chesterbrook, Pennsylvania and Zug, Switzerland-based LifeScan business, which sells the OneTouch line of connected and non-connected glucometers.

Digital therapeutics may be up and coming, but they also have a long way to go before their mainstream treatment options, according to experts who spoke at the digital therapeutics deep dive at HIMSS18.

Artificial intelligence has been working its way into the field of research.

Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia.

Its not uncommon to see customers paying for coffee or boarding a flight using a QR code from their smartphone, but some researchers are now looking to create an edible medication QR code.